Abstract:Major depression is a common and severe psychiatric disorder with a highly polygenic genetic architecture. Genome-wide association studies have successfully identified multiple independent genetic loci that harbour variants associated with major depression, but the exact causal genes and biological mechanisms are largely unknown. Tissue-specific network approaches may identify molecular mechanisms underlying major depression and provide a biological substrate for integrative analyses. We provide a framework for the identification of individual risk genes and gene co-expression networks using genome-wide association summary statistics and gene expression information across multiple human brain tissues and whole blood. We developed a novel gene-based method called eMAGMA that leverages tissue-specific eQTL information to identify 99 biologically plausible risk genes associated with major depression, of which 58 are novel. Among these novel associations is Complement Factor 4A (C4A), recently implicated in schizophrenia through its role in synaptic pruning during postnatal development. Major depression risk genes were enriched in gene co-expression modules in multiple brain tissues and the implicated gene modules contained genes involved in synaptic signalling, neuronal development, and cell transport pathways. Modules enriched with major depression signals were strongly preserved across brain tissues, but were weakly preserved in whole blood, highlighting the importance of using disease-relevant tissues in genetic studies of psychiatric traits. We identified tissue-specific genes and gene co-expression networks associated with major depression. Our novel analytical framework can be used to gain fundamental insights into the functioning of the nervous system in major depression and other brain-related traits.Although genome-wide association studies have identified genetic risk variants associated with major depression, our understanding of the mechanisms through which they influence disease susceptibility remains largely unknown. Genetic risk variants are highly enriched in non-coding regions of the genome and affect gene expression. Genes are co-expressed and regulate the activity of one another to form highly organized networks. In this study, we generate tissue-specific gene co-expression networks, each containing groups of functionally related genes or "modules", to delineate gene co-expression and thereby facilitate the identification of gene processes in major depression. We developed and applied a novel research methodology (called "eMAGMA") which integrates genetic and transcriptomic information in a tissue-specific analysis to identify risk genes and test for their enrichment in gene co-expression modules. Using this novel approach, we identified gene modules in multiple tissues that are both enriched with major depression genetic association signals and biologically meaningful pathways. We also show the disease implicated gene modules are strongly preserved across brain regions, but not in whole blood, suggesting unique patterns of gene co-expression within the two tissue types. Our novel analytical framework provides important insights into the functional genetics major depression and can be applied to other neuropsychiatric disorders.

Transcriptome-wide Association Study Identifies New Susceptibility Genes and Pathways for Depression

A single-nucleus transcriptome-wide association study implicates novel genes in depression pathogenesis

Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression

Transcriptome-Wide Association Study Provides Insights Into the Genetic Component of Gene Expression in Anxiety

Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood

Epigenetic Element-Based Transcriptome-Wide Association Study Identifies Novel Genes for Bipolar Disorder

Whole exome sequencing identified six novel genes for depressive symptoms

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Brain transcriptome-wide association study implicates novel risk genes underlying schizophrenia risk

Regulatory Mechanisms of Major Depressive Disorder Risk Variants

Integrative analysis of transcriptome-wide association study and mRNA expression profile identified risk genes for bipolar disorder

DeepWAS: Directly Integrating Regulatory Information into GWAS Using Deep Learning Supports Master Regulator MEF2C As Risk Factor for Major Depressive Disorder

A gene co-expression network-based analysis of multiple brain tissues reveals novel genes and molecular pathways underlying major depression

A Conserved BDNF, Glutamate- and GABA-Enriched Gene Module Related to Human Depression Identified by Coexpression Meta-Analysis and DNA Variant Genome-Wide Association Studies

Key Risk Genes Identified From the Postmortem Brain of Patients With Major Depressive Disorder and Their Potential Clinical Applications

Weighted Gene Co-Expression Network Analysis Identifies Specific Modules and Hub Genes Related to Subsyndromal Symptomatic Depression

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Targeted Exome Sequencing Identifies Five Novel Loci at Genome-Wide Significance for Modulating Antidepressant Response in Patients with Major Depressive Disorder

A Joint Study of Whole Exome Sequencing and Structural MRI Analysis in Major Depressive Disorder.

Exome-wide screening identifies novel rare risk variants for major depression disorder

The Gene Encoding Protocadherin 9 ( PCDH9 ), a Novel Risk Factor for Major Depressive Disorder